acquired
Stage
2
Investors
About
Corimmun was a German drug-developing biotech company focused on novel therapeutics and diagnostics for cardiovascular diseases, including heart failure and arteriosclerosis. Its lead compound, COR-1, was in early clinical development for the treatment of heart failure.
Explore Corimmun's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.